Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSC 001

Next Previous
Drug Profile

NSC 001

Alternative Names: AF 267B; NGX-267; NI-004; NSC-001

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Life Science Research Israel
  • Developer Neurimmune Therapeutics; NSC-Therapeutics; Raptor Pharmaceutical Corp
  • Class Antidementias; Nootropics; Piperidines; Small molecules; Spiro compounds; Thiazolidines
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Cognition disorders; Lewy body disease; Xerostomia

Most Recent Events

  • 20 Aug 2025 Discontinued - Phase-I for Alzheimer's disease in USA (PO) (prior to August 2025) (Neurimmune Therapeutics pipeline, May 2021) (NSC Therapeutics pipeline, August 2025)
  • 20 Aug 2025 Discontinued - Phase-I for Lewy body disease (PO) (prior to August 2025) (Neurimmune Therapeutics pipeline, May 2021) (NSC Therapeutics pipeline, August 2025)
  • 20 Aug 2025 Phase-II clinical trials in Alzheimer's disease (PO) (prior to August 2025) (Neurimmune Therapeutics pipeline, May 2021) (NSC Therapeutics pipeline, August 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top